FLT3-IN-28
FLT3-IN-28 (Compound 12y) is an orally active FLT3 inhibitor with antitumor activity. FLT3-IN-28 selectively inhibits cancer cells harboring the FLT3 internal tandem duplication (ITD) mutation, with IC50 values of 85, 290, 130, 65, and 220 nM for BaF3-FLT3-ITD, BaF3-TEL-VEGFR2, MV4-11, MOLM-13, and MOLM-14 cell lines respectively (MV4-11 and MOLM-13/14 are acute myeloid leukemia (AML) cell lines carrying the FLT3-ITD mutation) . Additionally, FLT3-IN-28 can downregulate the phosphorylation levels of FLT3 and STAT5 in MOLM-13 cells and induce cell cycle arrest and Apoptosis. FLT3-IN-28 has an oral bioavailability of 19.2% in SD rats and can prolong survival in a dose-dependent manner in NSG mice xenografted with MOLM-13 cells. FLT3-IN-28 holds promise for research in cancer fields related to FLT3-ITD[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; FLT3; STAT
Related Pathways
Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(N1CC(O)C1)NC2=CC(OC3=CC=C(NC(C4=CN(C5=CC=CN=C5)N=N4)=O)C=C3F)=CC=N2
Molecular Formula
C23H19FN8O4
Molecular Weight
490.45
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
STAT5
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ACTH (Adrenocorticotrophic Hormone) (Pituitary Marker) (CLIP/2040R), 0.2mg/mL
Mouse IL-1RA Recombinant Rabbit monoclonal Antibody
NALP12 (NLRP12) (NM_144687) Human Over-expression Lysate
